|
A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) Clinical research trials and A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT). A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) clinical trial. Participants oftentimes recieve the most expert healthcare available for their A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT) condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT)  A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT)
A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT)
For Condition: Deep Vein Thrombosis
Status: Recruiting
Sponsor(s): Sanofi-Synthelabo ,
Synopsis: Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectible anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Confirmed acute symptomatic DVT - Written informed consent Exclusion Criteria - Legal lower age limitations - Patients with symptomatic pulmonary embolism - Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT - Other indication for VKA than DVT - More than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of VKA treatment prior to randomization - Participation in another pharmacotherapeutic study within the prior 30 days - Creatinine clearance <10mL/min, severe hepatic disease or bacterial endocarditis - Life expectancy <3 Months - Active bleeding or high risk for bleeding - Uncontrolled hypertension: systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg. - Pregnancy or childbearing potential without proper contraceptive measures - Any other contraindication listen in the labeling of warfarin, acenocoumarol, UFH, enoxaparin, or tinzaparin
Total Enrollment:
Location and Contact Information:
Scott and White Memorial Hospital & Clinic *Recruiting*
Temple, Texas, 76508
United States
Recruiting Susan Dent 254-724-4206
Consultants in Pulmonary Medicine *Recruiting*
Olathe, Kansas, 66061
United States
Recruiting Diane Thorson 913-829-0446
Swedish Medical Center *Recruiting*
Seattle, Washington, 98122
United States
Recruiting Bruce Davidson 206-215-2500
Health System Research Center *Recruiting*
Grand Forks, North Dakota, 58201
United States
Recruiting Dianne Vold 701-780-1559
William Dittman *Recruiting*
Spokane, Washington, 99203
United States
Recruiting William Dittman 509-474-3065
DeKalb Medical Center *Recruiting*
Decatur, Georgia, 30033-6136
United States
Recruiting Michael Calvert 404-499-0533
Lehigh Valley Hospital *Recruiting*
Allentown, Pennsylvania, 18103
United States
Recruiting Study Coordinator 610-402-8999
University of Oklahoma HSC *Recruiting*
Oklahoma City, Oklahoma, 73104
United States
Recruiting Penny Razo-Mosier 405-271-4742
Boston Medical Center *Recruiting*
Boston, Massachusetts, 02118
United States
Recruiting Jack Ansell 617-638-7250
University of Rochester Medical Center *Recruiting*
Rochester, New York, 14642
United States
Recruiting Karen Helles 585-275-0803
North Shore University Hospital *Recruiting*
Manhasset, New York, 11030
United States
Recruiting Marjorie Fricano 516-562-8942
MIMA Century Research Associates *Recruiting*
Melbourne, Florida, 32901
United States
Recruiting Mima Reseach Associate 321-723-1203
Pulmonary Associates *Recruiting*
Fredericksburg, Virginia, 22401
United States
Recruiting Valerie Muntem 540-372-3684
Evanston Northwestern Healthcare *Recruiting*
Evanston, Illinois, 60201
United States
Recruiting Karen Hathaway 847-570-1438
St. Joseph Mercy - Oakland Research Center *Recruiting*
Pontiac, Michigan, 48341
United States
Recruiting Terri Taylor 248-858-6767
Medical College of Georgia *Recruiting*
Augusta, Georgia, 30912
United States
Recruiting Melissa James 706-721-8391
James Muntz *Recruiting*
Houston, Texas, 77030
United States
Recruiting James Muntz 713-986-5572
Loyola University of Chicago *Recruiting*
Maywood, Illinois, 60513
United States
Recruiting Cathy Kalnicky 708-216-2027
University of Colorado Health Sciences Center *Recruiting*
Denver, Colorado, 80129
United States
Recruiting Michelle Anderson 303-315-8842
Jackson Cardio-Vascular Clinic *Recruiting*
Jacksonville, Florida, 32216
United States
Recruiting Kim Teeter 904-828-5573
McGuire VAMC *Recruiting*
Richmond, Virginia, 23249
United States
Recruiting Michelle Nichols 804-675-5000
Northwestern University *Recruiting*
Chicago, Illinois, 60611
United States
Recruiting Molly Beals 312-238-1269
Inova Alexandria Hospital *Recruiting*
Alexandria, Virginia, 22304
United States
Recruiting James Cooper 703-504-7950
Lovelace Health Systems *Recruiting*
Albuquerque, New Mexico, 87108
United States
Recruiting Alex Spyropoulous 505-262-7874
Additional Information:
Study ID Numbers: EFC3491/64717;
Study Start Date: July 2003
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067093
Other Deep Vein Thrombosis Studies:
1. Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
2. A safety and efficacy trial evaluating the use of SanOrg34006 compared to placebo in patients who have completed 6 months of treatment for symptomatic pulmonary embolism or deep vein thrombosis
3. A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT)
Related Studies:
Other Deep Vein Thrombosis Clinical Trials
Other Georgia Clinical Trials
Other Decatur Clinical Trials
A safety and efficacy trial evaluating the use of SanOrg34006 in the treatment of Deep Vein Thrombosis (DVT)
|
|
|
|
|
|
|
|
